Teacher Retirement System of Texas increased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 121.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,407 shares of the company's stock after buying an additional 24,337 shares during the period. Teacher Retirement System of Texas' holdings in Cellebrite DI were worth $863,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Bosun Asset Management LLC raised its holdings in Cellebrite DI by 1.4% during the 4th quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock worth $954,000 after purchasing an additional 584 shares during the last quarter. TD Waterhouse Canada Inc. raised its holdings in Cellebrite DI by 1.8% during the 4th quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock worth $1,046,000 after purchasing an additional 859 shares during the last quarter. Fox Run Management L.L.C. raised its holdings in Cellebrite DI by 8.2% during the 4th quarter. Fox Run Management L.L.C. now owns 34,334 shares of the company's stock worth $756,000 after purchasing an additional 2,598 shares during the last quarter. NewEdge Advisors LLC raised its holdings in Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the last quarter. Finally, Gen Wealth Partners Inc bought a new position in Cellebrite DI during the 4th quarter worth approximately $85,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the stock. Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of Cellebrite DI in a report on Friday, June 6th. JPMorgan Chase & Co. lowered their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI currently has an average rating of "Buy" and a consensus target price of $22.43.
View Our Latest Analysis on Cellebrite DI
Cellebrite DI Stock Down 0.7%
NASDAQ:CLBT traded down $0.11 during trading hours on Friday, reaching $14.44. The company had a trading volume of 409,597 shares, compared to its average volume of 1,459,388. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -15.06, a P/E/G ratio of 2.87 and a beta of 1.28. The business's 50-day simple moving average is $16.31 and its two-hundred day simple moving average is $19.03. Cellebrite DI Ltd. has a twelve month low of $11.90 and a twelve month high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The business had revenue of $107.55 million during the quarter, compared to analysts' expectations of $109.36 million. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The business's quarterly revenue was up 20.0% on a year-over-year basis. During the same period last year, the company posted $0.08 earnings per share. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles

Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.